Literature DB >> 20588232

Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.

Marek Nowak1, Ewa Glowacka, Marian Szpakowski, Krzysztof Szyllo, Andrzej Malinowski, Andrzej Kulig, Henryk Tchorzewski, Jan Wilczynski.   

Abstract

OBJECTIVE: To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status. We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.
DESIGN: Prospective study.
SETTING: Tertiary referral hospital. POPULATION: 51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.
METHODS: The levels of cytokines were measured using ELISA sets.
RESULTS: We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors. Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors. Moreover, women with very advanced cancer in whom the optimal cytoreduction was disabled had the highest serum levels of IL-10, TGF-beta1 and IL-8. The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors. The areas under curves constructed for the selected cutoff serum cytokines levels (AUC-ROC) showed good predictive values for IL-6 (0.87), IL-10 (0.836) and IL-8 (0.797).
CONCLUSIONS: Our results indicate on intensified inflammatory process in women with ovarian cancer (accompanied by their immunosuppression). Preoperative analysis of serum IL-6, IL-10 and IL-8 may improve the differential diagnosis of ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20588232

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  35 in total

1.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

Review 2.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  J Mol Med (Berl)       Date:  2013-09-21       Impact factor: 4.599

3.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

4.  Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Authors:  An Coosemans; Judit Decoene; Thaïs Baert; Annouschka Laenen; Ahmad Kasran; Tina Verschuere; Sven Seys; Ignace Vergote
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

5.  Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.

Authors:  Nicola Hardwick; Jonathan A Ledermann; Egla Aitkens; Benny Chain
Journal:  Cancer Immunol Immunother       Date:  2012-04-05       Impact factor: 6.968

6.  Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells.

Authors:  Deok-Soo Son; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  J Inflamm (Lond)       Date:  2013-06-25       Impact factor: 4.981

7.  Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer.

Authors:  Timucin Mermer; Mustafa Cosan Terek; Burak Zeybek; Ahmet Mete Ergenoglu; Ahmet Ozgur Yeniel; Aydın Ozsaran; Osman Zekioglu
Journal:  J Gynecol Oncol       Date:  2012-04-03       Impact factor: 4.401

8.  Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours.

Authors:  Aleksandra Mielczarek-Palacz; Zdzisława Kondera-Anasz; Justyna Sikora
Journal:  Arch Med Sci       Date:  2012-10-30       Impact factor: 3.318

9.  Endometriosis-associated ovarian cancer: a review of pathogenesis.

Authors:  Michael J Worley; William R Welch; Ross S Berkowitz; Shu-Wing Ng
Journal:  Int J Mol Sci       Date:  2013-03-06       Impact factor: 5.923

10.  IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer.

Authors:  Kevin M Hart; Katelyn T Byrne; Michael J Molloy; Edward M Usherwood; Brent Berwin
Journal:  Front Immunol       Date:  2011-07-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.